Clinical Trial: SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)

U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07745114) titled 'SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)' on July 22.

Brief Summary: This study is divided into 3 parts: Part A, Part B, and Part C. Part A is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of SAL0137 tablets; Part B is a randomized, double-blind, placebo-controlled, multiple ascending dose study with once-daily administration for 14 consecutive days to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple QD oral doses of SAL0137 tablets....